Parkinson's Disease Dementia Can Be Easily Detected in Routine Clinical Practice

被引:36
作者
Dujardin, Kathy [1 ]
Dubois, Bruno [2 ]
Tison, Francois [3 ]
Durif, Franck [4 ]
Bourdeix, Isabelle [5 ]
Pere, Jean-Jacques [5 ]
Duhamel, Alain [6 ]
机构
[1] Univ Lille, Med Ctr, Univ Lille Nord France, UDSL,CNRS FRE3291,Neurol & Movement Disorders Uni, Lille, France
[2] Univ Paris 06, Salpetriere Hosp, AP HP, INSERM UPMC UMRS 610, Paris, France
[3] Univ Bordeaux, Dept Neurol, Bordeaux Univ Med Ctr, Bordeaux, France
[4] Univ Clermont Ferrand, Med Ctr, Gabriel Montpied Hosp, Dept Neurol, Clermont Ferrand, France
[5] Novartis Pharma SAS, Rueil Malmaison, France
[6] Univ Lille, Med Ctr, Univ Lille Nord France, UDSL,EA2694,Biostat Dept, Lille, France
关键词
Parkinson's disease; dementia; cognition; screening procedures; basal ganglia; MONTREAL COGNITIVE ASSESSMENT; ALZHEIMERS-DISEASE; DIAGNOSTIC-CRITERIA; BEDSIDE ASSESSMENT; PREVALENCE; RIVASTIGMINE; IMPAIRMENT; VALIDITY; DECLINE; PROFILE;
D O I
10.1002/mds.23391
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease (PD) is mainly characterized by its motor manifestations, but it is also frequently associated with dementia. Early diagnosis of PD dementia (PDD) is particularly important because effective cholinesterase inhibitor treatments are available. This study aimed at validating a short procedure for screening for PDD in routine clinical practice and which adopts recently published diagnostic criteria. One hundred eighty-eight patients with PD participated in the study. The examination procedure comprised three steps: standard clinical examination, a short cognitive function assessment fulfilling the requirements of the Movement Disorders Society (Mini Mental State Examination, five-word test, word generation task, and impact on daily life, including a questionnaire on compliance with medication) and an extensive evaluation of cognitive functions and behavior. After each step, the suspected presence or absence of dementia was recorded. After the short cognitive function assessment, PDD was suspected in 18.62% of the patients [95% confidence interval (CI): 13.32-24.93%]. After the extensive assessment, 21.81% (95% CI: 16.13-28.40%) met the criteria for probable PDD. The short battery's sensitivity and specificity were 65.85% (95% CI = 49.41-79.92%) and 94.56% (95% CI = 89.56-97.62%), respectively. A stepwise logistic regression analysis showed that use of a specific cutoff considerably enhanced the short battery's sensitivity (85.37%, 95% CI = 70.83-94.43%) without decreasing its specificity (83.67%, 95% CI = 76.69-89.25%). With an easy-to-use, short battery of tests that are commonly used in routine clinical practice, it is possible to diagnose PDD in accordance with reference criteria and with the same sensitivity and specificity as in a more extensive evaluation. (C) 2010 Movement Disorder Society
引用
收藏
页码:2769 / 2776
页数:8
相关论文
共 50 条
[31]   Cognitive Reserve in Parkinson's Disease without Dementia: β-Amyloid and Metabolic Assessment [J].
Fernandez-Rodriguez, Beatriz ;
Rodriguez-Rojas, Rafael ;
Guida, Pasqualina ;
Angulo-Diaz-Parreno, Santiago ;
Trompeta, Clara ;
Mata-Marin, David ;
Obeso, Ignacio ;
Vela, Lydia ;
de las Heras, Isabel Plaza ;
Obeso, Jose A. ;
Gasca-Salas, Carmen .
MOVEMENT DISORDERS CLINICAL PRACTICE, 2024, 11 (03) :282-288
[32]   DEPRESSION AND DEMENTIA IN PARKINSON'S DISEASE [J].
Akyol, Ali ;
Ozkul, Ayca ;
Telli-Turgut, Eylem ;
Yilmaz, Emine ;
Akyildiz, Utku ;
Memis, Sakine .
TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2011, 14 (04) :295-299
[33]   Dementia in idiopathic Parkinson's disease [J].
Sommer, U ;
Reichmann, H .
NERVENHEILKUNDE, 2001, 20 (02) :65-+
[34]   Longitudinal analysis of functional disabilities, cognitive decline and risk of dementia in women with Parkinson's disease and detrusor overactivity [J].
Campos-Sousa, Raimundo Nonato ;
de Sousa, Icaro Araujo ;
Almeida, Kelson James ;
Dias de Castro, Inacio Augusto ;
Soares de Oliveira-Filho, Marconi Cosme ;
Quagliato, Elizabeth M. A. B. .
JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 75 :85-88
[35]   Evaluating Rivastigmine in Mild-to-Moderate Parkinson's Disease Dementia Using ADAS-Cog Items [J].
Schmitt, Frederick A. ;
Aarsland, Dag ;
Bronnick, Kolbjorn S. ;
Meng, Xiangyi ;
Tekin, Sibel ;
Olin, Jason T. .
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2010, 25 (05) :407-413
[36]   Conversion Between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 Scores in Parkinson's Disease [J].
van Steenoven, Inger ;
Aarsland, Dag ;
Hurtig, Howard ;
Chen-Plotkin, Alice ;
Duda, John E. ;
Rick, Jacqueline ;
Chahine, Lama M. ;
Dahodwala, Nabila ;
Trojanowski, John Q. ;
Roalf, David R. ;
Moberg, Paul J. ;
Weintraub, Daniel .
MOVEMENT DISORDERS, 2014, 29 (14) :1809-1815
[37]   Current and future clinical utilities of Parkinson's disease and dementia biomarkers: can they help us conquer the disease? [J].
Ho, Gilbert ;
Takamatsu, Yoshiki ;
Waragai, Masaaki ;
Wada, Ryoko ;
Sugama, Shuei ;
Takenouchi, Takato ;
Fujita, Masayo ;
Ali, Alysha ;
Hsieh, Mindy Hsin-I ;
Hashimoto, Makoto .
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (11) :1149-1161
[38]   Comparing Clinical Profiles in Alzheimer's Disease and Parkinson's Disease Dementia [J].
Farlow, Martin R. ;
Schmitt, Frederick ;
Aarsland, Dag ;
Grossberg, George T. ;
Somogyi, Monique ;
Meng, Xiangyi .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2013, 3 (01) :281-290
[39]   A quick test of cognitive speed can predict development of dementia in Parkinson's disease [J].
Jalakas, Mattis ;
Palmqvist, Sebastian ;
Hall, Sara ;
Svard, Daniel ;
Lindberg, Olof ;
Pereira, Joana B. ;
van Westen, Danielle ;
Hansson, Oskar .
SCIENTIFIC REPORTS, 2019, 9 (1)
[40]   Sequence of clinical and neurodegeneration events in Parkinson's disease progression [J].
Oxtoby, Neil P. ;
Leyland, Louise-Ann ;
Aksman, Leon M. ;
Thomas, George E. C. ;
Bunting, Emma L. ;
Wijeratne, Peter A. ;
Young, Alexandra L. ;
Zarkali, Angelika ;
Tan, Manuela M. X. ;
Bremner, Fion D. ;
Keane, Pearse A. ;
Morris, Huw R. ;
Schrag, Anette E. ;
Alexander, Daniel C. ;
Weil, Rimona S. .
BRAIN, 2021, 144 (03) :975-988